MedTrace Logo

Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea

NCT03667222 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 207

Last updated 2019-07-10

No results posted yet for this study

Summary

This is a 12-week, multicenter, double-blind, randomized, two-arm, vehicle controlled study. Subjects will be randomized 1:1 to BPX-04 minocycline topical gel 1% or vehicle. This study will include approximately 176 randomized subjects with inflammatory lesions of papulopustular rosacea on the face, defined by an IGA score of 3 (moderate) or 4 (severe) at Baseline. Subjects will be healthy male or female subjects aged 18 years or older. There will be up to 20 study sites in the USA.

Conditions

  • Papulopustular Rosacea

Interventions

DRUG

minocycline topical gel

Once daily administration of BPX-04 minocycline gel for 12 weeks

DRUG

topical gel vehicle

Once daily administration of BPX-04 gel vehicle for 12 weeks

Sponsors & Collaborators

  • BioPharmX, Inc.

    lead INDUSTRY

Principal Investigators

  • AnnaMarie Daniels · BioPharmX, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-18
Primary Completion
2019-05-17
Completion
2019-08-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03667222 on ClinicalTrials.gov